UK Department of Health Funding for a Zika and Chikungunya Vaccines

Situation

GRA worked in partnership with a European vaccine development company to lead an application for a non-dilutive funding for the clinical development of their vaccine portfolio. The funds were intended for the CMC, clinical and formulation development of their Zika and Chikungunya vaccines.

GRA Involvement

• Scoping of Chikunguyna and Zika vaccine business case
• Supported and led on applications for vaccine funding
• Development of CMC, preclinical and clinical project plan
• Interactions with Innovate UK SBRI scheme and CEPI

Value Added

GRA worked with Themis Biosciences GmbH to assemble a business case for the development of the Zika and Chikungunya vaccines, justifying how the funding could accelerate the programs into late phase clinical trials.  This case was put forward to the SBRI and CEPI review panels.  The application was described as ‘exemplary’ by the SBRI review panel and all applications were successful.   The projects were awarded a total of over GBP 20 million through Innovate UK for Zika and Chikungunya as well as further funding from CEPI for the Chikungunya program.

GRA successfully helped lead the applications to raise £3 million in non-dilutional funding to develop the vaccine.  GRA was also involved in project manage two of the contracts.

Click here to read what our clients have said about GRA.